MediWound posts investor presentation on enzymatic burn and chronic-wound therapies NexoBrid, EscharEx
MDWD•Investor presentation highlights NexoBrid and EscharEx
MediWound outlined a growth plan centered on NexoBrid, marketed for severe burn eschar removal, with 2025 revenue of USD 17 million.
EscharEx, an investigational chronic-wound debridement therapy, targets a USD 4 billion U.S. market; the VLU program is in Phase 3.
Cash position, warrant proceeds and manufacturing expansion
The company highlighted a cash balance of USD 36 million with no debt and cited runway through profitability.
The presentation flagged potential additional proceeds of up to USD 29 million from Series A warrant exercises expiring in November 2026.
MediWound also said a new cGMP sterile manufacturing facility is designed to expand capacity sixfold, with regulatory approvals expected in 2027.
